Diapulse develops and supplies a clinically validated Class III pulsed radio frequency energy device designed to support soft-tissue healing and recovery without drugs. Its technology is backed by more than 60 years of peer-reviewed research and has been used in applications ranging from postoperative recovery to burn care and athletic rehabilitation.
BioElectronics CorporationFounded by Andrew J. Whelan in 2000, Frederick-based BioElectronics Corporation develops and manufactures wearable, drug-free electroceutical devices that use pulsed shortwave therapy for pain management. The company operates as an OEM and works with commercial and international partners to bring its ActiPatch and RecoveryRx devices to consumer and clinical markets, with four FDA 510(k) clearances and published randomized clinical research supporting its technology.JEFFERSON, MD
Surgical Recovery SystemsAfter founder Scott H. Adams struggled to sleep in a recliner following rotator cuff surgery, Surgical Recovery Systems began making the patented Restore You Therapeutic Support, a U.S.-made positioning device for shoulder and post-surgical recovery. Founded in 2019, the company combines engineering with orthopedic clinical research to hold patients in a consistent recovery position while they sleep in their own beds. Restore You is used by surgical and orthopedic practices nationwide and is undergoing clinical study with Columbia University Hospital.FAIRFIELD TOWNSHIP, OH
GWR Medical, IncFounded in 1996 in Chadds Ford, Pennsylvania, privately owned GWR Medical develops FDA-cleared topical oxygen therapy devices for hard-to-heal open wounds and burns. Its home-based TO2 treatment is paired with WoundMatrix, the company’s wound-imaging and measurement technology, to help clinicians and insurers track healing remotely. GWR says its therapy has been provided to 15,000 patients and has been used by the Department of Defense and Veterans Administration.CHADDS FORD, PA
LifePulse CorporationLifePulse Corporation develops and manufactures its US-engineered Intellipulse® platform to deliver therapeutics directly into cells, with a focus on targeted oncology in human and veterinary medicine. Founded by Gary Strange, the Tampa Bay company builds on more than three decades of research, $35 million in non-dilutive funding, and over 100 issued patents. Its animal-health division has treated hundreds of dogs, cats, and horses since 2022, while its human-health program is advancing toward pancreatic-tumor trials.NEW YORK, NY